SSD vs Collagenase in Pediatric Burn Patients
Information source: Children's Mercy Hospital Kansas City
Information obtained from ClinicalTrials.gov on October 04, 2010 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Burns
Phase: N/A
Status: Recruiting
Sponsored by: Children's Mercy Hospital Kansas City Official(s) and/or principal investigator(s): Daniel J Ostlie, MD, Principal Investigator, Affiliation: Children's Mercy Hospital and Clinics
Overall contact: Daniel J Ostlie, MD, Phone: 816-234-3575, Email: dostlie@cmh.edu
Summary
The objective of this study is to evaluate the outcomes of children with burn injury with
regard to the utilization of Silver sulfadiazine (SSD) cream and Collagenase ointment. The
primary outcome variable will be need for skin grafting. The specific aim of the study is
to prospectively collect data to determine if SSD is superior to Collagenase with regard to
avoiding the need for skin grafting.
Clinical Details
Official title: A Prospective Comparison of Silver Sulfadiazine Cream and Collagenase Ointment for the Treatment of Burns in Children
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Need for skin grafting
Secondary outcome: Development of burn contractures
Detailed description:
During the treatment of burns, the wounds must be repeatedly debrided to remove loose and
adherent dead tissue (eschar) until it is determined that the wound will require skin
grafting for coverage or that the wound will re-epithelialize. The eschar associated with
burn injury eventually will separate from the burn bed through proteolytic enzymes that are
produced naturally in the skin or by colonizing bacteria. During this acute treatment
timeframe, agents are used that can help with removal of the eschar. SSD is an
antimicrobial agent that sterilizes the wound, thus preventing infection and allowing the
natural proteolytic enzymes in the skin to act on the eschar leading to separation during
the mechanical debridement treatment regimen. SSD was initially introduced in the 1960's
and has been a mainstay of treatment for the care of burns since. It is currently used in
the CMH burn unit.
Collagen is a protein that is highly present in skin (~75% of dry weight of skin), and is
the dominant protein that must be divided to allow for eschar separation. Collagenase is an
exogenous enzyme that breaks down native and denatured collagen. Collagenase will not
however breakdown healthy, normal collagen. Collagenase is FDA approved for the treatment
of burns and is now used by many burn units including the burn unit at CMH. Currently, in
this institution, both SSD and collagenase are being used for the removal of eschar.
Unfortunately, there has not been a properly performed prospective randomized comparison of
these two regimens in children, despite the widespread use of both regimens. Because of the
uncertain data regarding these approaches, as well as the fact that we currently perform
both approaches here, we feel that there is equipoise in regard to the techniques. We plan
to perform a prospective randomized trial comparing SSD and Collagenase in children that
sustain burns and are admitted to CMH for debridement of their burns. We have reviewed our
historical experience using collagenase and SSD. Utilizing the need for skin graft rates
from this historical population, a sample size of 75 patients in each arm has been
calculated. This sample size calculation was performed using a standard alpha and beta of
0. 05 and 0. 8, respectively, and assumes a 10% attrition rate. The primary endpoint for this
study will be the need for skin grafting in children that sustain a burn of sufficient depth
to require admission and debridement of eschar.
Eligibility
Minimum age: 2 Months.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Partial thickness burn
2. Less than 25% total body surface area burn
3. Less than 18 years of age
4. Greater than 2 months of age
Exclusion Criteria:
1. Greater than 25% total body surface burn
2. 18 years of age or older
3. Younger than 2 months of age
4. Allergy to sulfa
Locations and Contacts
Daniel J Ostlie, MD, Phone: 816-234-3575, Email: dostlie@cmh.edu
Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, United States; Recruiting Daniel J Ostlie, MD
Additional Information
Related publications: Hansbrough JF, Achauer B, Dawson J, Himel H, Luterman A, Slater H, Levenson S, Salzberg CA, Hansbrough WB, Doré C. Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream. J Burn Care Rehabil. 1995 May-Jun;16(3 Pt 1):241-7. Ozcan C, Ergün O, Celik A, Cördük N, Ozok G. Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns. Burns. 2002 Dec;28(8):791-4. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007 Mar;33(2):139-48. Epub 2006 Nov 29. Review.
Starting date: January 2008
Last updated: November 6, 2008
|